The MAP Group acquires German pharma and biotech consultancy SKC

British pharmaceutical and biotech consultancy The MAP Group has acquired SKC, a German firm specialised in market access and pricing services.

Based in Hannover, SKC is one of the leading German market access and pricing and reimbursement consultancies, working with pharma, biotech, medtech and digital health companies across Germany and the DACH region. Since its founding in 2005, SKC has grown to a team of over 30 staff.

Steve Glass, the CEO of The MAP Group, said the joining of SKC marks an exciting new chapter for the company in the important German market. “The overall goal of The MAP Group is to become Europe’s largest independent specialist pharmaceutical and biotechnology management consultancy. This acquisition is an important step to further expand our pan-European presence and support our German clients in the complex life science market.”

The MAP Group now has operations in the UK, Ireland, Benelux, and Germany, serving over 200 clients.

Following closing of the deal, SKC founders and managing partners Matthias Schönermark and Heike Kielhorn-Schönermark will become members of The MAP Group’s executive leadership team.

The deal follows The MAP Group’s Q2 acquisition of AxTalis, a Belgium-based consultancy that focuses on regulatory strategy, compliance, and medical affairs to the Benelux area. The MAP Group’s buy-and-build strategy is backed by Kester Capital.